$78.99
近くで: Nov 10 EDT
$77.74
-1.25-1.58%
プレマーケット: 8:36 AM EDT
Comments
Loading...
アナリストの評価、目標株価、予想
CVS Health Corp のコンセンサス目標株価は $85.48 で、26 人のアナリストの評価に基づいています。最高値は $103（10 7, 2025 に Wells Fargo が発表）、最安値は $66（12 3, 2024 に Deutsche Bank が発表）です。直近のアナリスト評価 3 件は TD Cowen、Evercore ISI Group、RBC Capital により 11 3, 2025、10 30, 2025、10 30, 2025 に発表されました。TD Cowen、Evercore ISI Group、RBC Capital の平均目標株価は $96 で、これらの最新評価から CVS Health Corp に対して 23.50% のupsideが示唆されています。
推奨アナリスト会社1
TD Cowen
Evercore ISI Group
RBC Capital
Cantor Fitzgerald
Truist Securities
1アナリスト評価から算出
CVS Healthのアナリスト評価
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/03/2025 | 28.65% | TD Cowen | $99 → $100 | Maintains | Buy | |||
10/30/2025 | 22.22% | Evercore ISI Group | $85 → $95 | Maintains | Outperform | |||
10/30/2025 | 19.64% | RBC Capital | $81 → $93 | Maintains | Outperform | |||
10/30/2025 | 22.22% | Cantor Fitzgerald | $78 → $95 | Maintains | Overweight | |||
10/30/2025 | 22.22% | Truist Securities | $92 → $95 | Reiterates | Buy → Buy | |||
10/24/2025 | 23.5% | UBS | $79 → $96 | Maintains | Buy | |||
10/14/2025 | 14.5% | Morgan Stanley | $82 → $89 | Maintains | Overweight | |||
10/14/2025 | 17.07% | Goldman Sachs | → $91 | Initiates | → Buy | |||
10/09/2025 | 13.21% | Mizuho | $76 → $88 | Maintains | Outperform | |||
10/07/2025 | 32.51% | Wells Fargo | $84 → $103 | Maintains | Overweight | |||
09/05/2025 | -0.94% | Bernstein | $72 → $77 | Maintains | Market Perform | |||
09/04/2025 | 11.93% | Barclays | $80 → $87 | Maintains | Overweight | |||
08/26/2025 | 0.35% | Cantor Fitzgerald | $78 → $78 | Reiterates | Overweight → Overweight | |||
08/18/2025 | 1.63% | UBS | $67 → $79 | Upgrade | Neutral → Buy | |||
08/14/2025 | 5.49% | Baird | $71 → $82 | Upgrade | Neutral → Outperform | |||
08/01/2025 | 5.49% | Morgan Stanley | $80 → $82 | Maintains | Overweight | |||
08/01/2025 | 2.92% | Barclays | $79 → $80 | Maintains | Overweight | |||
07/22/2025 | -13.8% | UBS | $71 → $67 | Maintains | Neutral | |||
06/30/2025 | 2.92% | Jefferies | $74 → $80 | Maintains | Buy | |||
06/02/2025 | 1.63% | Barclays | $82 → $79 | Maintains | Overweight | |||
05/12/2025 | 8.07% | Truist Securities | $82 → $84 | Maintains | Buy | |||
05/06/2025 | 8.07% | Wells Fargo | $76 → $84 | Maintains | Overweight | |||
05/05/2025 | 4.21% | RBC Capital | $74 → $81 | Maintains | Outperform | |||
05/02/2025 | -8.66% | UBS | $67 → $71 | Maintains | Neutral | |||
05/02/2025 | 5.49% | Barclays | $73 → $82 | Maintains | Overweight | |||
04/15/2025 | -8.66% | Baird | $51 → $71 | Maintains | Neutral | |||
04/11/2025 | 5.49% | Truist Securities | $76 → $82 | Maintains | Buy | |||
04/09/2025 | -2.23% | Mizuho | $70 → $76 | Maintains | Outperform | |||
03/21/2025 | -4.8% | Piper Sandler | $72 → $74 | Maintains | Overweight | |||
02/18/2025 | 4.21% | JP Morgan | $80 → $81 | Maintains | Overweight | |||
02/13/2025 | -6.09% | Wells Fargo | $68 → $73 | Maintains | Overweight | |||
02/13/2025 | -2.23% | Truist Securities | $60 → $76 | Maintains | Buy | |||
02/13/2025 | -6.09% | Barclays | $71 → $73 | Maintains | Overweight | |||
02/13/2025 | -3.51% | Leerink Partners | $55 → $75 | Upgrade | Market Perform → Outperform | |||
01/27/2025 | -16.38% | Evercore ISI Group | $60 → $65 | Maintains | Outperform | |||
01/06/2025 | -22.81% | Truist Securities | $67 → $60 | Maintains | Buy | |||
12/03/2024 | -15.09% | Deutsche Bank | $66 → $66 | Upgrade | Hold → Buy | |||
11/25/2024 | 2.92% | TD Cowen | $73 → $80 | Maintains | Buy | |||
11/25/2024 | -17.66% | Piper Sandler | $72 → $64 | Maintains | Overweight | |||
11/20/2024 | -13.8% | Truist Securities | $76 → $67 | Reiterates | Buy → Buy | |||
11/18/2024 | -15.09% | Wells Fargo | $60 → $66 | Upgrade | Equal-Weight → Overweight | |||
11/15/2024 | -25.38% | RBC Capital | $68 → $58 | Maintains | Outperform | |||
11/07/2024 | -20.24% | UBS | $60 → $62 | Maintains | Neutral | |||
11/07/2024 | -8.66% | Barclays | $75 → $71 | Maintains | Overweight | |||
11/04/2024 | -22.81% | Wells Fargo | $61 → $60 | Maintains | Equal-Weight | |||
10/24/2024 | -15.09% | Mizuho | $73 → $66 | Maintains | Outperform | |||
10/23/2024 | -3.51% | Barclays | $82 → $75 | Maintains | Overweight | |||
10/11/2024 | -2.23% | Truist Securities | $66 → $76 | Maintains | Buy | |||
10/10/2024 | 5.49% | Barclays | $63 → $82 | Upgrade | Equal-Weight → Overweight | |||
10/08/2024 | -3.51% | Evercore ISI Group | $62 → $75 | Maintains | Outperform | |||
10/04/2024 | 9.35% | TD Cowen | $59 → $85 | Upgrade | Hold → Buy | |||
10/01/2024 | -20.24% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/16/2024 | -20.24% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/10/2024 | -20.24% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/04/2024 | -12.52% | RBC Capital | $68 → $68 | Reiterates | Outperform → Outperform | |||
08/19/2024 | -20.24% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
08/12/2024 | -21.52% | Wells Fargo | $60 → $61 | Maintains | Equal-Weight | |||
08/09/2024 | -18.95% | Deutsche Bank | $64 → $63 | Maintains | Hold | |||
08/08/2024 | -18.95% | Barclays | $65 → $63 | Maintains | Equal-Weight | |||
08/08/2024 | -20.24% | Cantor Fitzgerald | $58 → $62 | Maintains | Neutral | |||
08/08/2024 | -20.24% | Evercore ISI Group | $65 → $62 | Maintains | Outperform | |||
07/23/2024 | -25.38% | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
06/12/2024 | -25.38% | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
05/30/2024 | 10.64% | JP Morgan | $101 → $86 | Maintains | Overweight | |||
05/30/2024 | -21.52% | Baird | → $61 | Initiates | → Neutral | |||
05/08/2024 | 2.92% | Argus Research | $100 → $80 | Maintains | Buy | |||
05/07/2024 | -22.81% | Wells Fargo | $76 → $60 | Maintains | Equal-Weight | |||
05/07/2024 | -24.1% | TD Cowen | $99 → $59 | Downgrade | Buy → Hold | |||
05/02/2024 | -0.94% | B of A Securities | $95 → $77 | Maintains | Buy | |||
05/02/2024 | -4.8% | Goldman Sachs | $85 → $74 | Maintains | Buy | |||
05/02/2024 | -18.95% | Barclays | $78 → $63 | Maintains | Equal-Weight | |||
05/02/2024 | -22.81% | UBS | $85 → $60 | Downgrade | Buy → Neutral | |||
05/02/2024 | -15.09% | Truist Securities | $90 → $66 | Reiterates | Buy → Buy | |||
05/02/2024 | -7.37% | Mizuho | $86 → $72 | Maintains | Buy | |||
05/01/2024 | -22.81% | Leerink Partners | → $60 | Downgrade | Outperform → Market Perform | |||
05/01/2024 | -25.38% | Cantor Fitzgerald | $87 → $58 | Downgrade | Overweight → Neutral | |||
04/10/2024 | 11.93% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
04/08/2024 | -2.23% | Wells Fargo | $83 → $76 | Maintains | Equal-Weight | |||
04/04/2024 | 11.93% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
03/15/2024 | 20.93% | Piper Sandler | $93 → $94 | Maintains | Overweight | |||
03/06/2024 | 0.35% | Barclays | → $78 | Initiates | → Equal-Weight | |||
02/26/2024 | 13.21% | Leerink Partners | → $88 | Initiates | → Outperform | |||
02/08/2024 | 11.93% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
02/08/2024 | 8.07% | RBC Capital | $86 → $84 | Maintains | Outperform | |||
12/22/2023 | 20.93% | HSBC | → $94 | Initiates | → Buy | |||
12/11/2023 | 27.36% | TD Cowen | $102 → $99 | Maintains | Outperform | |||
11/21/2023 | 11.93% | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
11/02/2023 | 10.64% | Mizuho | $88 → $86 | Maintains | Buy | |||
11/02/2023 | 10.64% | RBC Capital | $91 → $86 | Maintains | Outperform | |||
11/02/2023 | 28.65% | Morgan Stanley | $110 → $100 | Maintains | Overweight | |||
09/19/2023 | 6.78% | Evercore ISI Group | $81 → $83 | Upgrade | In-Line → Outperform | |||
09/14/2023 | 11.93% | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
09/12/2023 | 2.92% | Wolfe Research | → $80 | Upgrade | Peer Perform → Outperform | |||
09/01/2023 | 5.49% | Piper Sandler | $85 → $82 | Maintains | Overweight | |||
08/18/2023 | 17.07% | RBC Capital | → $91 | Reiterates | Outperform → Outperform | |||
08/18/2023 | — | Edward Jones | — | Downgrade | Buy → Hold | |||
08/04/2023 | 9.35% | Raymond James | $90 → $85 | Maintains | Outperform | |||
08/03/2023 | 26.08% | Truist Securities | $103 → $98 | Maintains | Buy | |||
08/03/2023 | 41.52% | Morgan Stanley | $120 → $110 | Maintains | Overweight | |||
08/03/2023 | 17.07% | RBC Capital | $102 → $91 | Maintains | Outperform |
よくある質問
CVS Health (CVS) 株の目標株価はいくらですか?
CVS Healthの最新目標株価CVS Health。(NYSE:CVS) の最新目標株価をTD Cowenが11 3, 2025日に発表した。このアナリスト会社はCVS Health ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内（28.63% upsideの可能性あり）と予想する$100.00の目標株価を設定しました。過去1年間に42のアナリスト会社がレーティングを報告しています。
CVS Health (CVS Healthの直近のアナリスト評価は？(CVS) の直近のアナリスト評価は？
CVS Healthの最新のアナリストレーティングはCVS Healthです。(NYSE:CVS) の最新のアナリストレーティングはTD Cowenによるもので、CVS HealthのCVS Healthです。{actionCompany}}のbuy評価です。
CVS Health (CVSの直近のアップグレードはいつですか？(CVS) の最後のアップグレードはいつですか？
CVS Health Corpの最後のアップグレードは8 18, 2025日に行われ、UBSは目標株価を$79に引き上げました。companyName}}のUBSの以前のa neutralは$79でした。
CVS Health (CVS Healthの直近の格下げ日はいつですか？(CVS) の最後の格下げはいつですか？
CVS Health Corpの最後の格下げは5 7, 2024日にTD CowenがCVS Health Corpの目標株価を$99から$59に変更した時です。
CVS Health (CVS Healthの次のアナリストレーティングはいつ発表・更新されますか？(CVS) の次の格付けはいつですか？
アナリストは、公開財務諸表を調べたり、CVS Healthの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは11 3, 2025日に提出されましたので、次のレーティングは11 3, 2026日あたりに提出されるものと思われます。
CVS HealthのアナリストレーティングはCVS Healthですか？(CVS) は正しいですか？
レーティングは主観的なものであり変化しますが、最新のCVS Health (CVS) (CVS) のレーティングは維持で、目標株価は$99.00から$100.00でした。現在の価格 CVS Health ({{exchange}}) (CVS) の現在の取引価格は$77.74で、これはアナリストの予測レンジout ofです。
ブラウズ アナリスト評価と目標株価 全銘柄の
こんな人も見ています
© 2025 Benzinga | All Rights Reserved